Octreopharm

OctreoPharm Sciences is a German biopharmaceutical company specializing in the development of innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumors. The company's core expertise lies in its theranostic platform, which utilizes somatostatin receptor (SSTR) antagonists to improve tumor uptake and retention compared to traditional agonists. Its lead programs, OPS201 and OPS202, were designed as a matched pair for therapy and imaging, respectively. In 2015, the company was acquired by Ipsen to bolster its oncology portfolio and expand its presence in the radiotherapeutics market. This acquisition allowed Ipsen to integrate next-generation peptide-based receptor antagonists into its existing somatostatin analog franchise. The technology continues to be developed under Ipsen's pipeline, focusing on precision medicine in oncology.